Skip to main content
SpringerLink
Log in

Recombinant erythropoietin (Epogen) improves cardiac exercise performance in children with end-stage renal disease

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

To determine the effects of anemia in children with end-stage renal disease, we studied cardiac performance before and 1 and 6 months after recombinant erythropoietin (Epogen). Children with end-stage renal disease were included if they had significant anemia [hematocrit (Hct)<30%]. Epogen 50 U/kg was given subcutaneously or intravenously three times per week until the Hct was ≥33%. Echocardiography, cardiac output (acetylene rebreathing), and treadmill (modified Bruce) tests were performed. Boys (9) and girls (9), 11.9±5.6 years, were given Epogen and the Hct increased (from 21.7±2.7% to 33.4±2.1%,P=0.001). Heart rate decreased (P=0.04) and stroke volume did not change. Blood pressure did not change. Cardiac thickness, chamber dimensions, left ventricular wall stress, velocity of circumferential fiber shortening, and indices of diastolic function were normal and did not change after Epogen. Exercise time increased (from 10.3±1.9 to 11.2±1.9 min,P=0.01) after 1 month of Epogen. Resting oxygen consumption (VO2) decreased (from 7.8±1.8 to 6.9±1.4 ml/min per kg,P=0.01) 1 month after Epogen and peak exercise VO2 did not change after Epogen. There were no differences in exercise tests between the 1 and 6 month measurements. Exercise tolerance improves after the short-term correction of anemia and there is no further improvement after long-term correction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. D'Cruz IA, Bhatt GR, Cohen HC, Glick G (1978) Echocardiographic detection of cardiac involvement in patients with chronic renal failure. Arch Intern Med 138: 720–724

    PubMed  Google Scholar 

  2. Capelli JP, Kasparian H (1977) Cardiac work demands and left ventricular function in end-stage renal disease. Ann Intern Med 86: 261–267

    PubMed  Google Scholar 

  3. Drueke T, Le Pailleur C, Meilhac B, Koutoudis C, Zingraff J, DiMatteo J, Crosnier J (1977) Congestive cardiomyopathy in uremic patients on long term haemodialysis. BMJ 1: 350–353

    PubMed  Google Scholar 

  4. Ianhez LE, Lowen J, Sabbaga E (1975) Uremic myocardiopathy. Nephron 15: 17–28

    PubMed  Google Scholar 

  5. Raab W (1944) Cardiotoxic substances in the blood and heart muscle in uremia (their nature and action). J Lab Clin Med 29: 715–734

    Google Scholar 

  6. Scheuer J, Stzoski SW (1973) The effects of uremic compounds on cardiac function and metabolism. J Mol Cell Cardiol 5: 287–300

    PubMed  Google Scholar 

  7. Scheuer J, Nivatpumin T, Yipintsoi T (1975) Effects of moderate uremia on cardiac contractile responses. Proc Soc Exp Biol Med 150: 471–474

    PubMed  Google Scholar 

  8. Henrich WL, Hunt JM, Nixon JV (1984) Increased ionized calcium and left ventricular contractility during hemodialysis. N Engl J Med 310: 19–23

    PubMed  Google Scholar 

  9. Colan SD, Sanders SP, Ingelfinger JR, Harmon W (1987) Left ventricular mechanics and contractile state in children and young adults with end-stage renal disease: effect of dialysis and renal transplantation. J Am Coll Cardiol 10: 1085–1094

    PubMed  Google Scholar 

  10. Cohen MV, Scheuer J (1979) Echocardiographic assessment of left ventricular function in patients with chronic uremia. Clin Nephrol 12: 156–162

    PubMed  Google Scholar 

  11. Muller-Wiefel DE, Scigalla P (1988) Specific problems of renal anemia in childhood. Contrib Nephrol 66: 71–84

    PubMed  Google Scholar 

  12. Silberberg JS, Rahal DP, Patton R, Sniderman AD (1989) Role of anemia in the pathogenesis of left ventricular hypertrophy in endstage renal disease. Am J Cardiol 64: 222–224

    PubMed  Google Scholar 

  13. Schafer GE, Kaltenbach M, Schoeppe W (1984) Hemodynamic response to chronic anemia in renal failure. Contrib Nephrol 41: 428–432

    PubMed  Google Scholar 

  14. Hung J, Harris PJ, Uren RF, Tiller DJ, Kelly DT (1980) Uremic cardiomyopathy-effect of hemodialysis on left ventricular function in end-stage renal failure. N Engl J Med 302: 547–551

    PubMed  Google Scholar 

  15. Ikaheimo M, Huttunen K, Takkunen J (1981) Cardiac effects of chronic renal failure and hemodialysis treatment. Hypertensive versus normotensive patients. Br Heart J 45: 710–716

    PubMed  Google Scholar 

  16. Nixon JV, Mitchell JH, McPhaul JJ, Henrich WL (1983) Effects of hemodialysis on left ventricular function. Dissociation of changes in filling volume and in contractile state. J Clin Invest 71: 377–384

    PubMed  Google Scholar 

  17. Florenzano F, Diaz G, Regonesi C, Escobar E (1984) Left ventricular function in chronic anemia: evidence of noncatecholamine positive inotropic factor in the serum. Am J Cardiol 54: 638–645

    PubMed  Google Scholar 

  18. Goldberg A, Hagberg J, Delmez J, Haynes ME, Harter HR (1980) The metabolic effects of exercise training in hemodialysis patients. Kidney Int 18: 754–761

    PubMed  Google Scholar 

  19. Painter P, Zimmerman S (1986) Exercise in end stage renal disease. Am J Kidney Dis 7: 386–394

    PubMed  Google Scholar 

  20. Kettner-Melsheimer A, Weiss M, Huber W (1987) Physical work capacity in chronic renal disease. Int J Artif Organs 10: 23–30

    PubMed  Google Scholar 

  21. Woodson R (1984) Hemoglobin concentration and exercise capacity. Am Rev Respir Dis 129: S72-S75

    PubMed  Google Scholar 

  22. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM (1986) Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet II: 1175–1178

    Google Scholar 

  23. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316: 73–78

    PubMed  Google Scholar 

  24. Sundal E, Kaeser U (1989) Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 4: 979–987

    PubMed  Google Scholar 

  25. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, VanStone JC, VanWyck DB, Zuckerman K, Adamson JW (1989) Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111: 992–1000

    PubMed  Google Scholar 

  26. Scigalla P, Bonzel KE, Bulla M, Burghard R, Dippel J, Geisert J, Leumann E, Lilien TV, Muller-Wiefel DE, Offner G, Pistor K, Zoellner K (1989) Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease. Contrib Nephrol 76: 227–241

    PubMed  Google Scholar 

  27. Montini G, Zacchello G, Baraldi E, Zanconato S, Suppiej A, Fabris F, Andreetta B, Pavanello L, Zacchello F (1990) Benefits and tisk of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis. J Pediatr 117: 556–560

    PubMed  Google Scholar 

  28. Rosenlof K, Gronhagen-Riska C, Sovijarvi A, Honkanen E, Tikkanen I, Ekstrand A, Piirila P, Fyhrquist F (1989) Beneficial effects of erythropoietin on haematological parameters, aerobic capacity, and body fluid composition in patients on haemodialysis. J Intern Med 226: 311–317

    PubMed  Google Scholar 

  29. Lundin AP (1989) Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy. Semin Nephrol 9 [Suppl 1]: 22–29

    PubMed  Google Scholar 

  30. Nissenson AR (1989) Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life. Semin Nephrol 9 [Suppl 2]: 25–31

    PubMed  Google Scholar 

  31. Macdougall IC, Lewis NP, Sauders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KA, Coles GA, Williams JD (1990) Long term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335: 489–493

    PubMed  Google Scholar 

  32. Robertson HT, Haley NR, Guthrie M, Cardenas D, Eschbach JW, Adamson JW (1990) Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis 15: 325–332

    PubMed  Google Scholar 

  33. Baraldi E, Montini G, Zanconato S, Zacchello G, Zacchello F (1990) Exercise tolerance after anemia correction with recombinant human erythropoietin in end-stage renal disease. Pediatr Nephrol 4: 623–626

    PubMed  Google Scholar 

  34. Feigenbaum H (1986) Echocardiographic evaluation of cardiac chambers. In: Feigenbaum H (eds) Echocardiography, 4th edn. Lea and Febiger, Philadelphia, pp 127–187

    Google Scholar 

  35. Colan SD, Borow KM, Neumann A (1984) Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load independent index of myocardial contractility. J Am Coll Cardiol 4: 715–724

    PubMed  Google Scholar 

  36. Reichek N, Wilson J, St John Sutton M, Plappert TA, Goldberg S, Hirshfeld (1982) Noninvasive determination of left ventricular endsystolic stress: validation of the method and initial application. Circulation 65: 99–108

    PubMed  Google Scholar 

  37. Mehmel HC, Stockins B, Ruffmann K, Olshausen KV, Schuler G, Kubler W (1981) The linearity of the end-systolic pressure volume relationship in man and its sensitivity for assessment of left ventricular function. Circulation 63: 1216–1222

    PubMed  Google Scholar 

  38. Snider AR, Gidding SS, Rocchini AP, Rosenthal A, Dick M, Crowley DC, Peters J (1985) Doppler evaluation of left ventricular diastolic filling in children with systemic hypertension. Am J Cardiol 56: 921–926

    PubMed  Google Scholar 

  39. James FW, Blomqvist CG, Freed MD, Miller WW, Moller JH, Nugent EW, Riopel DA, Strong WB, Wessel HU (1982) Standards for exercise testing in the pediatric age group. Circulation 66: 1377A-1397A

    PubMed  Google Scholar 

  40. Sackner MA, Greeneltch D, Heiman MS, Epstein S, Atkins N (1975) Diffusing capacity, membrane diffusing capacity, capillary blood volume, pulmonary tissue volume, and cardiac output measured by a rebreathing technique. Am Rev Respir Dis 111: 157–165

    PubMed  Google Scholar 

  41. London GM, Zins B, Pannier B, Naret C, Berthelot JM, Jacquot C, Safar M, Drueke TB (1989) Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36: 878–882

    PubMed  Google Scholar 

  42. Grutzmacher P, Scheuermann E, Low I, Bergmann M, Rauber K, Baum R, Heuser J, Schoeppe W (1988) Correction of renal anaemia by recombinant human erythropoietin: effects on myocardial function. Contrib Nephrol 66: 176–184

    PubMed  Google Scholar 

  43. Low I, Grutzmacher P, Bergmann M, Schoeppe W (1989) Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol 31: 26–30

    PubMed  Google Scholar 

  44. Evans RW, Rader B, Manninen DL (1990) The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263: 825–830

    PubMed  Google Scholar 

  45. Wolcott DL, Marsh JT, La Rue A, Carr C, Nissenson AR (1989) Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 14: 478–485

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA

    Gerard R. Martin, Mary E. Turner & Edward J. Ruley

  2. Department of Cardiology, Children's National Medical Center, Washington, District of Columbia, USA

    Gerard R. Martin & Elaine S. Skurow

  3. Department of Nephrology, Children's National Medical Center, Washington, District of Columbia, USA

    Jose R. Ongkingo, Mary E. Turner & Edward J. Ruley

Authors
  1. Gerard R. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jose R. Ongkingo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mary E. Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elaine S. Skurow
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Edward J. Ruley
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, G.R., Ongkingo, J.R., Turner, M.E. et al. Recombinant erythropoietin (Epogen) improves cardiac exercise performance in children with end-stage renal disease. Pediatr Nephrol 7, 276–280 (1993). https://doi.org/10.1007/BF00853220

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00853220

Key words

Search

Navigation